Company Overview and News

UEM Sunrise, T7, Reach Energy, MMC Corp, Gamuda, MCE Holdings and IHH Healthcare

2018-10-08 theedgemarkets
KUALA LUMPUR (Oct 8): Based on corporate announcements and news flow today, companies in focus on Tuesday (Oct 9) may include: UEM Sunrise Bhd, T7 Global Bhd, Reach Energy Bhd, MMC Corp Bhd, Gamuda Bhd, MCE Holdings Bhd and IHH Healthcare Bhd.
5148 5225 7245 Q0F IHHHF 5256 0131 5001

Pahang Crown Princess appointed Diversified Gateway chairperson

2018-10-08 theedgemarkets
KUALA LUMPUR (Oct 8): Pahang Crown Princess Tengku Datuk Aishah Ahmad Shah has been appointed as the non-executive chairman of Diversified Gateway Solutions Bhd.
7245 0131 5001

Stock With Momentum: Mieco Chipboard

2018-08-16 theedgemarkets
TRADING of shares in Mieco Chipboard Bhd (fundamental: 0.45/3, valuation: 1.8/3) triggered our momentum algorithm yesterday for the first time this year. The group saw 12.86 million shares traded compared to its 200-day average of 2.47 million.
BSMAF 1818 5001

Mieco ready to test higher, says AllianceDBS Research

2018-07-25 theedgemarkets
KUALA LUMPUR (July 26): AllianceDBS Research said Mieco Chipboard Bhd (Mieco) had on July 25 tested previous day’s high of 48.5 sen before closing near the day’s high at 48 sen (up 1 sen or 2.12%).

Shares of furniture players gain on potential increase in demand amid US-China trade war

2018-07-23 theedgemarkets
KUALA LUMPUR (July 23): Interest in shares of export-oriented furniture manufacturers spiked, following news the United States is looking to impose a 10% tariff on more than 5,000 new Chinese imports worth US$200 billion, which includes furniture.
7006 7088 5101 LIIHF 5001

Furniture and glove makers winners in US-China trade war

In the rubber glove sector, possible winners (but receiving only minimal spillover benefits) are Top Glove Corp Bhd, Hartalega Holdings Bhd and Kossan Rubber Industries Bhd.
TGLVY 7113 TPGVF 7006 7153 5168 7022 5101 GBTKF LIIHF HRGHY 5001

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...